Τίτλος:
Regression of neovascular age-related macular degeneration following
infliximab therapy
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
PURPOSE: To describe the effects of the antitumor necrosis factor (TNF)
monoclonal antibody Infliximab systemic therapy on choroidal
neovacularisation (CNV) secondary to age-related macular degeneration
(AMD).
DESIGN: Prospective, noncomparative series of three patients.
METHODS: A subretinal membrane secondary to AMD was documented by
fluoroangiography at baseline in three elderly patients scheduled to
receive Infliximab therapy for inflammatory arthritis (infusions of 5
mg/kg at weeks 0, 2, 6, and every 8 weeks thereafter). Follow-up was
performed at three months post-baseline, as well as during 18 months of
continuing treatment in the first patient.
RESULTS: CNV regressed partially at three months and resolved at six
months in the first patient. Best-corrected visual acuity (BCVA)
increased from 0.05 to 0.2; this effect was sustained at 18 months.
Regression of subretinal membrane and increase of BCVA was also
documented in the other patients. No ocular or extra-ocular side effects
were noted.
CONCLUSIONS: These findings suggest a plausible pathogenetic role of TNF
in CNV secondary to AMD. Additional patients should he studied to
confirm the promising clinical results. (c) 2005 by Elsevier Inc. All
rights reserved.
Συγγραφείς:
Markomichelakis, NN
Theodossiadis, PG
Sfikakis, PP
Περιοδικό:
AJO. AMERICAN JOURNAL OF OPHTHALMOLOGY
Εκδότης:
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI:
10.1016/j.ajo.2004.09.058
